Tumorresponse monitoring in patients with breast cancer treated with primary systemic therapy: Towards predicting response in both the primary tumor and in axillary lymph nodes.

Philips0 个研究点目标入组 300 人开始时间: 待定最近更新: 2024年6月11日

适应症

试验速览

•1. Proven infiltrating breast cancer with either a primary tumor over 3 cm in size (clinical examination) or cytologically proven spread to the axillary lymph nodes;
•2. Stage II or stage III disease (revised AJCC staging system 2001). 'Locally advanced breast cancer' patients are consequently eligible, including those with ipsilateral supraclavicular lymph node metastases. In stage II patients with T1N1 disease, N1 status must have been demonstrated by either fine needle aspiration from an axillary lymph node or by a metastasis of over 2 mm in diameter at sentinel node biopsy. Stage IIA patients are only eligible if the tumor is over 3 cms in diameter;

•1. Evidence of distant metastases. Staging examinations must have included a chest roentgenogram, an ultrasound examination of the liver and an isotope bone scan. Abnormal uptake on the isotope bone scan can only be accepted if bone metastases were excluded by MRI;
•2.Previous radiation therapy or chemotherapy;

发起方